Brief: Fresenius SE - Denosumab CHMP Positive Opinion
May 27 (Reuters) - FRESENIUS SE & CO KGAA FREG.DE: DENOSUMAB CHMP POSITIVE OPINION Further company coverage: FREG.DE (Gdansk Newsroom) ((((gdansk.newsroom@thomsonreuters.com ; +48 587785269; ));))
Recent news on Fresenius SE & Co. KGaA
See all newsFresenius lifts 2026 expectations after strong Q3 (updated)
Healthcare firm Fresenius Q3 revenue rises on Kabi growth; lifts outlook
Brief: Fresenius Sees FY26 EBIT Margin Above 11.5%
Brief: Fresenius SE Q3 Revenue EUR 5,803 Million
Fresenius signs biosimilars pipeline agreement with WuXi Biologics (updated)